WASHINGTON, Oct. 31,
2023 /PRNewswire/ -- Danaher Corporation (NYSE:
DHR) ("Danaher" or the "Company"), a leading global life sciences
and diagnostics innovator, today announced that Christopher
Riley has been appointed by its Board of Directors to be
Executive Vice President of Danaher with responsibility for its
Biotechnology business, effective January 1, 2024. Mr. Riley,
currently Vice President and Group Executive of Danaher's Life
Sciences company with responsibility for Genomic Medicines, will
become an executive officer of Danaher reporting to President and
Chief Executive Officer, Rainer
Blair.
Rainer Blair commented:
"Chris' leadership has helped drive the success of our genomic
medicines and diagnostics businesses over the past six years. His
strong track record of delivering results, passion for helping our
customers and building winning teams, plus his deep commitment to
the Danaher Business System, is a tremendous asset for Danaher. I
look forward to seeing Chris apply his skills and experiences to
ensuring the continued success of our Biotechnology business, as we
support customers in their pursuit of life-changing breakthroughs
for patients."
Mr. Riley joined Danaher in 2007. In his current role, in
addition to his Genomic Medicines responsibilities, Chris oversees
High Growth Markets and Pall Corporation at Danaher. Previously he
was Vice President and Group Executive for Danaher's Diagnostics
company and, prior to that, held various roles of increasing
responsibility across multiple Danaher subsidiaries. Before joining
Danaher, Chris worked for the Boston Consulting Group. He holds a
Bachelor of Science degree in Mechanical Engineering from the
University of Illinois, as well as a
Master of Business Administration degree from Kellogg at
Northwestern University.
ABOUT DANAHER
Danaher is a leading global life
sciences and diagnostics innovator, committed to accelerating the
power of science and technology to improve human health. Our
businesses partner closely with customers to solve many of the most
important health challenges impacting patients around the world.
Danaher's advanced science and technology - and proven ability to
innovate - help enable faster, more accurate diagnoses and help
reduce the time and cost needed to sustainably discover, develop
and deliver life-changing therapies. Focused on scientific
excellence, innovation and continuous improvement, our 65,000+
associates worldwide help ensure that Danaher is improving quality
of life for billions of people today, while setting the foundation
for a healthier, more sustainable tomorrow. Explore more
at www.danaher.com.
FORWARD-LOOKING STATEMENTS
Statements in this release
that are not strictly historical, including the statement regarding
the future success of our Biotechnology business and any other
statements regarding events or developments that we believe or
anticipate will or may occur in the future are "forward-looking"
statements within the meaning of the federal securities laws. There
are a number of important factors that could cause actual results,
developments and business decisions to differ materially from those
suggested or indicated by such forward-looking statements and you
should not place undue reliance on any such forward-looking
statements. These factors include, among other things, potential
future, adverse impacts on our business, results of operations and
financial condition related to the COVID-19 pandemic, the impact of
our debt obligations on our operations and liquidity, deterioration
of or instability in the economy, the markets we serve and the
financial markets, uncertainties relating to national laws or
policies, including laws or policies to protect or promote domestic
interests and/or address foreign competition, contractions or
growth rates and cyclicality of markets we serve, competition, our
ability to develop and successfully market new products and
technologies and expand into new markets, the potential for
improper conduct by our employees, agents or business partners, our
compliance with applicable laws and regulations (including rules
relating to off-label marketing and other regulations relating to
medical devices and the health care industry), the results of our
clinical trials and perceptions thereof, our ability to effectively
address cost reductions and other changes in the health care
industry, our ability to successfully identify and consummate
appropriate acquisitions (including the pending acquisition of
Abcam) and strategic investments and successfully complete
divestitures and other dispositions, our ability to integrate the
businesses we acquire and achieve the anticipated growth, synergies
and other benefits of such acquisitions, contingent liabilities and
other risks relating to acquisitions, investments, strategic
relationships and divestitures (including tax-related and other
contingent liabilities relating to past and future IPOs, split-offs
or spin-offs), security breaches or other disruptions of our
information technology systems or violations of data privacy laws,
the impact of our restructuring activities on our ability to grow,
risks relating to potential impairment of goodwill and other
intangible assets, currency exchange rates, tax audits and changes
in our tax rate and income tax liabilities, changes in tax laws
applicable to multinational companies, litigation and other
contingent liabilities including intellectual property and
environmental, health and safety matters, the rights of
the United States government with
respect to our production capacity in times of national emergency
or with respect to intellectual property/production capacity
developed using government funding, risks relating to product,
service or software defects, product liability and recalls, risks
relating to fluctuations in the cost and availability of the
supplies we use (including commodities) and labor we need for our
operations, our relationships with and the performance of our
channel partners, uncertainties relating to collaboration
arrangements with third-parties, the impact of deregulation on
demand for our products and services, the impact of climate change,
legal or regulatory measures to address climate change and our
ability to address stakeholder expectations relating to climate
change, labor matters and our ability to recruit, retain and
motivate talented employees representing diverse backgrounds,
experiences and skill sets, non-U.S. economic, political, legal,
compliance, social and business factors (including the impact of
military conflicts), disruptions relating to man-made and natural
disasters, pension plan and healthcare costs, inflation and the
impact of our By-law exclusive forum provisions. Additional
information regarding the factors that may cause actual results to
differ materially from these forward-looking statements is
available in our SEC filings, including our 2022 Annual Report on
Form 10-K and Quarterly Report on Form 10-Q for the third quarter
of 2023. These forward-looking statements speak only as of the date
of this release and except to the extent required by applicable
law, the Company does not assume any obligation to update or revise
any forward-looking statement, whether as a result of new
information, future events and developments or otherwise.
Danaher Corporation, 2200 Pennsylvania Avenue, N.W., Suite
800W, Washington, D.C. 20037,
Telephone: (202) 828-0850, Fax: (202) 828-0860
View original
content:https://www.prnewswire.com/news-releases/danaher-appoints-christopher-riley-to-executive-vice-president-for-biotechnology-301972310.html
SOURCE Danaher Corporation
